Navigation Links
Fate Therapeutics Granted Exclusive License By The Regents of the University of California to Stem Cell Modulators for Osteo-Regeneration

LA JOLLA, Calif., July 1 /PRNewswire/ -- Fate Therapeutics, Inc. announced today that it has acquired exclusive intellectual property rights covering small molecule compositions and methods for inducing bone formation from The Regents of the University of California. These proprietary osteogenic agents were developed by Farhad Parhami, Ph.D., professor of medicine at University of California, Los Angeles, in collaboration with Michael Jung, Ph.D., professor of chemistry and biochemistry, and have been shown in vivo to exhibit osteo-regenerative activity. While many current medications aimed at addressing bone deficiencies work by preventing further decay, osteogenic agents stimulate positive bone growth and may offer an improved course of action in orthopedic medicine ranging from bone fractures to osteoporosis. The exclusive rights acquired today by Fate Therapeutics continue to bolster the Company's platform of Stem Cell Modulators (SCMs) - small molecules and biologics that seek to modulate adult stem cells within the body to guide cell fate for therapeutic purposes.

"Dr. Parhami and his research team have not only advanced the understanding of the biology around bone formation but also identified and created small molecules that may be used to induce the differentiation of adult stem cells in the body for osteo-regenerative medicine," said Paul Grayson, president and CEO of Fate Therapeutics. "The potential of these novel small molecules has been confirmed in several different in vivo proof of concept studies, and we look forward to their continued preclinical development for bone generation."

Adult stem cells are naturally-occurring cells found in almost all tissues or organs in the body and are primarily responsible for maintaining and repairing their native tissue. For example, mesenchymal stem cells are multipotent cells that can differentiate into a variety of cell types, including osteoblasts, chondrocytes, myocytes and adipocytes. Dr. Parhami's discovery of specific pathways and small molecules that can induce differentiation to mature, bone-forming osteoblasts offers a new mechanism of intervention, which may be applied to treat a number of bone injuries and conditions, including non-union fracture, spinal fusion or osteoporosis. By collaborating with the foremost researchers and clinicians in the field of adult stem cell biology, Fate Therapeutics is continuing to expand its leadership position in the discovery and development of SCMs for regenerative medicine.

"Having an industry partner is essential to a successful translational drug discovery project, and we are excited about our collaboration with Fate Therapeutics to realize the full potential of our discoveries," said Dr. Parhami. "Our work has uncovered novel strategies and mechanisms for lineage-specific differentiation to an osteoblast phenotype. The ability to activate specific populations of stem cells in the body to promote bone regeneration may have many orthopedic clinical applications."

Dr. Parhami continued, "For example, with traumatic bone injuries, such as non-union fractures where the break in the bone cannot be healed without medical intervention, patients must undergo complicated surgeries and long recovery times. In the case of degenerative bone diseases, such as osteoporosis, current therapies focus on blocking bone degeneration rather than inducing formation. Being able to promote bone growth with novel osteogenic small molecules represents the next-generation of therapeutic agents for orthopedic medicine."

About Fate Therapeutics, Inc.

Fate Therapeutics is interrogating adult stem cell biology and applying induced pluripotent stem cell (iPSC) technology to develop Stem Cell Modulators (SCMs), small molecule or biologic compounds that guide cell fate for therapeutic purposes. Fate's approach has broad therapeutic potential in areas such as regenerative medicine, hematological diseases, metastatic cancer, traumatic injury and degenerative diseases. The Company is currently conducting a Phase 1b clinical trial of FT1050, a small molecule SCM designed to increase hematopoietic stem cell number and function in dual umbilical cord blood transplant recipients with hematologic malignancies. In addition, Fate Therapeutics and Stemgent have formed an alliance - CATALYST - a collaborative program to provide its members with first access to the most advanced iPSC technologies for drug discovery and development. Fate Therapeutics is headquartered in La Jolla, CA. For more information, please visit

SOURCE Fate Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Hyperion Therapeutics Raises $60 Million Series C
2. Cornerstone Therapeutics Joins the Russell 3000(R) Index
3. Global Autoimmune Disease Therapeutics Market to Reach $50 Billion by 2015, According to a New Report by Global Industry Analysts
4. Intrinsic Therapeutics Barricaid and Magellan Spine Technologies DART to Drive European Annulus Repair Market
5. Cell Therapeutics Completes Pixantrone NDA Submission and Requests Priority Review
6. Prospect Therapeutics Inc.s GCS-100 Has Focused on Developing Treatment for Three Blood-Borne Cancers
7. Cell Therapeutics Announces Final Results of its Fixed Price Exchange Offers for Any and All of its $118.9 Million Convertible Notes Outstanding
8. Transition Therapeutics Announces Appointment of Vice-President of Clinical Operations
9. Leaders from the Field of Pain Therapeutics to Discuss Latest Discoveries and Breakthroughs at Arrowhead's 3rd Annual Pain Therapeutics Summit
10. Echo Therapeutics and Handok Pharmaceuticals Sign South Korea License for Needle-free Symphony(TM) Transdermal Continuous Glucose Monitoring System
11. Cell Therapeutics Announces Preliminary Results of its Fixed Price Exchange Offers for Any and All of its $118.9 Million Convertible Notes Outstanding
Post Your Comments:
(Date:10/13/2015)... ... , ... Sir Grout of Greater Boston donated an expansive, seven room ... House Charities® (RMHC®). This donation was made in an effort to give back to ... inception. , “We believe strongly in the Ronald McDonald House Charities, and they are ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... its newest technology platform, ENGAGE, at HIMSS’s Patient Engagement Summit . HealthAware ... , ENGAGE delivers innovative health programs and interventions via mobile devices that provide ...
(Date:10/13/2015)... ... October 13, 2015 , ... Element ... products, introduced a new company, RightSensor™ LLC, an Internet of Things (IoT) hardware ... RightSensor™ provides a fully-managed approach for customers requiring sensor hardware for critical data ...
(Date:10/13/2015)... ... , ... NavaFit Inc. today announced the launch of its NavaFit app for ... local fitness & sporting events, and stay motivated. Users can download the ... us to get more serious about fitness and wellness, individuals are constantly looking for ...
(Date:10/13/2015)... , ... October 13, 2015 ... ... Omega-3, a first-of-its kind product that targets the unique health needs of ... of the American Pregnancy Association ( ), utilizes Nordic Naturals’ exclusive, ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... , Oct. 13, 2015  A minimally-invasive treatment just ... the United States.  After more than 10 years of ... 9 approved the use of High Intensity Focused Ultrasound ... cells while protecting surrounding tissue and minimizing chances for ... George Suarez , a pioneering Miami ...
(Date:10/13/2015)... N.J. , Oct. 13, 2015  ContraVir ... the "Company"), a biopharmaceutical company focused on the ... announced the closing of its previously announced underwritten ... stock and warrants to purchase up to 3,000,000 ... fixed combined price to the public of $3.00. ...
(Date:10/13/2015)... , Oct. 13, 2015  Measurement in accountable ... and balancing financial incentives, but gaps in measurement ... care and health systems. A new, peer-reviewed ... Managed Care explores measurement gaps for ... sets. --> --> ...
Breaking Medicine Technology: